MaxCyte, Inc. Depreciation and Amortization Expense
MaxCyte, Inc. (MXCT) reported Depreciation and Amortization Expense of $953.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DepreciationAndAmortization · last filed 2026-08-13
- MaxCyte, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2026-06-30 was $953.00K, a 11.76% decline year-over-year.
- MaxCyte, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2026-03-31 was $1.02M, a 4.24% decline year-over-year.
- MaxCyte, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2025-12-31 was $1.04M, a 2.06% increase year-over-year.
- MaxCyte, Inc. depreciation, depletion and amortization, nonproduction for the quarter ending 2025-09-30 was $1.04M, a 2.25% increase year-over-year.
- MaxCyte, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2025 was $4.23M, a 2.00% increase from fiscal 2024.
- MaxCyte, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2024 was $4.14M, a 3.96% increase from fiscal 2023.
- MaxCyte, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2023 was $3.98M, a 57.63% increase from fiscal 2022.
- MaxCyte, Inc. depreciation, depletion and amortization, nonproduction for fiscal 2022 was $2.53M, a 87.38% increase from fiscal 2021.
| Period end | Depreciation, Depletion and Amortization, Nonproduction 3 month | Depreciation, Depletion and Amortization, Nonproduction 3 month as first filed | Depreciation, Depletion and Amortization, Nonproduction 6 month | Depreciation, Depletion and Amortization, Nonproduction 6 month as first filed | Depreciation, Depletion and Amortization, Nonproduction 9 month | Depreciation, Depletion and Amortization, Nonproduction 9 month as first filed | Depreciation, Depletion and Amortization, Nonproduction 12 month | Depreciation, Depletion and Amortization, Nonproduction 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $953.00K 10-Q · filed 2026-08-13 | $1.97M 10-Q · filed 2026-08-13 | $3.01M derived: sum of 3 quarters · filed 2026-08-13 | $4.05M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $1.02M 10-Q · filed 2026-05-13 | $2.06M derived: sum of 2 quarters · filed 2026-05-13 | $3.10M derived: sum of 3 quarters · filed 2026-05-13 | $4.18M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.08M derived: sum of 2 quarters · filed 2026-03-25 | $3.17M derived: sum of 3 quarters · filed 2026-08-13 | $4.23M 10-K · filed 2026-03-25 | ||||
| 2025-09-30 | $1.04M 10-Q · filed 2025-11-13 | $2.12M derived: sum of 2 quarters · filed 2026-08-13 | $3.19M 10-Q · filed 2025-11-13 | $4.21M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $1.08M 10-Q · filed 2026-08-13 | $2.14M 10-Q · filed 2026-08-13 | $3.16M derived: sum of 3 quarters · filed 2026-08-13 | $4.18M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $1.06M 10-Q · filed 2026-05-13 | $2.08M derived: sum of 2 quarters · filed 2026-05-13 | $3.10M derived: sum of 3 quarters · filed 2026-05-13 | $4.14M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $2.04M derived: sum of 2 quarters · filed 2026-03-25 | $3.08M derived: sum of 3 quarters · filed 2026-03-25 | $4.14M 10-K · filed 2026-03-25 | ||||
| 2024-09-30 | $1.02M 10-Q · filed 2025-11-13 | $2.06M derived: sum of 2 quarters · filed 2025-11-13 | $3.12M 10-Q · filed 2025-11-13 | $4.19M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $1.03M 10-Q · filed 2025-08-06 | $2.10M 10-Q · filed 2025-08-06 | $3.17M derived: sum of 3 quarters · filed 2025-08-06 | $4.20M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $1.07M 10-Q · filed 2025-05-08 | $2.13M derived: sum of 2 quarters · filed 2025-05-08 | $3.16M derived: sum of 3 quarters · filed 2025-05-08 | $4.14M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $2.10M derived: sum of 2 quarters · filed 2025-03-11 | $3.07M derived: sum of 3 quarters · filed 2025-03-11 | $3.98M 10-K · filed 2025-03-11 | ||||
| 2023-09-30 | $1.03M 10-Q · filed 2024-11-06 | $1.03M 10-Q · filed 2023-11-08 | $2.01M derived: sum of 2 quarters · filed 2024-11-06 | $2.92M 10-Q · filed 2024-11-06 | $2.92M 10-Q · filed 2023-11-08 | $3.80M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $977.00K 10-Q · filed 2024-08-06 | $977.40K 10-Q · filed 2023-08-09 | $1.89M 10-Q · filed 2024-08-06 | $1.89M 10-Q · filed 2023-08-09 | $2.76M derived: sum of 3 quarters · filed 2024-08-06 | $3.47M derived: sum of 4 quarters · filed 2024-08-06 | ||
| 2023-03-31 | $912.00K 10-Q · filed 2024-05-07 | $912.20K 10-Q · filed 2023-05-10 | $1.79M derived: sum of 2 quarters · filed 2024-05-07 | $2.50M derived: sum of 3 quarters · filed 2024-05-07 | $2.99M derived: sum of 4 quarters · filed 2024-05-07 | |||
| 2022-12-31 | $873.70K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $1.58M derived: sum of 2 quarters · filed 2024-03-12 | $2.08M derived: sum of 3 quarters · filed 2024-03-12 | $2.53M 10-K · filed 2024-03-12 | $2.53M 10-K · filed 2023-03-15 | |||
| 2022-09-30 | $709.80K 10-Q · filed 2023-11-08 | $1.21M derived: sum of 2 quarters · filed 2023-11-08 | $1.65M 10-Q · filed 2023-11-08 | $2.04M derived: sum of 4 quarters · filed 2023-11-08 | ||||
| 2022-06-30 | $497.10K 10-Q · filed 2023-08-09 | $944.50K 10-Q · filed 2023-08-09 | $1.33M derived: sum of 3 quarters · filed 2023-08-09 | $1.66M derived: sum of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | $447.30K 10-Q · filed 2023-05-10 | $828.90K derived: sum of 2 quarters · filed 2023-05-10 | $1.16M derived: sum of 3 quarters · filed 2023-05-10 | $1.48M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | $381.60K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $714.70K derived: sum of 2 quarters · filed 2023-03-15 | $1.04M derived: sum of 3 quarters · filed 2023-03-15 | $1.35M 10-K · filed 2023-03-15 | ||||
| 2021-09-30 | $333.10K 10-Q · filed 2022-11-09 | $366.00K 10-Q · filed 2021-11-10 | $656.00K derived: sum of 2 quarters · filed 2022-11-09 | $967.50K 10-Q · filed 2022-11-09 | $1.01M 10-Q · filed 2021-11-10 | $1.22M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $322.90K 10-Q · filed 2022-08-10 | $325.00K 10-Q · filed 2021-09-13 | $634.40K 10-Q · filed 2022-08-10 | $641.40K 10-Q · filed 2021-09-13 | $891.10K derived: sum of 3 quarters · filed 2022-08-10 | $1.18M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $311.60K 10-Q · filed 2022-05-09 | $568.20K derived: sum of 2 quarters · filed 2022-05-09 | $858.50K derived: sum of 3 quarters · filed 2022-05-09 | $1.11M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $256.60K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | $546.90K derived: sum of 2 quarters · filed 2022-03-22 | $803.40K derived: sum of 3 quarters · filed 2022-03-22 | $1.03M 10-K · filed 2022-03-22 | ||||
| 2020-09-30 | $290.30K 10-Q · filed 2021-11-10 | $546.80K derived: sum of 2 quarters · filed 2021-11-10 | $768.50K 10-Q · filed 2021-11-10 | |||||
| 2020-06-30 | $256.50K 10-Q · filed 2021-09-13 | $478.20K 10-Q · filed 2021-09-13 | ||||||
| 2019-12-31 | $541.30K 10-K · filed 2022-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |